Skip to main content
Top
Published in: Familial Cancer 2/2022

01-04-2022 | Breast Cancer | Original Article

The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1

Authors: Ashley Crook, Rebekah Kwa, Sarah Ephraums, Mathilda Wilding, Lavvina Thiyagarajan, Jane Fleming, Katrina Moore, Yemima Berman

Published in: Familial Cancer | Issue 2/2022

Login to get access

Abstract

Women with neurofibromatosis type 1 (NF1) have an increased risk of developing early breast cancer with a poorer prognosis compared to the general population. Therefore, international management guidelines recommend regular screening in women with NF1 starting from 30 to 35 years. As the psychological impacts of breast cancer screening in other high-risk populations cannot be extended to women with NF1, due to increased incidence of cognitive and mental health issues, the psychological harms of breast screening in women with NF1 are unknown. Consequently, the aim of this study was to assess the psychological impact of breast cancer screening in women with NF1 attending an established risk management clinic. Twenty-eight women with NF1 (30–50 years) completed psychological well-being and patient experience questionnaires, administered across five time points, before and after their initial and second round annual breast screening visits. Preliminary findings demonstrated the screening regimen was well-tolerated, with most participants reporting high satisfaction with the screening process. Overall, no significant increase in psychological distress related to the breast screening process was identified, with mean cancer worry and anxiety scores decreasing over time. However, some women did experience negative aspects of screening and barriers to re-attendance at annual breast screening appointments. As some women with NF1 exhibited clinical levels of psychological distress prior to screening, efforts to identify those at risk and additional support to address concerns and expectations throughout the breast screening process may be beneficial.
Appendix
Available only for authorised users
Literature
10.
go back to reference Easton DF, Ponder MA, Huson SM, Ponder BA (1993) An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 53(2):305–313PubMedPubMedCentral Easton DF, Ponder MA, Huson SM, Ponder BA (1993) An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 53(2):305–313PubMedPubMedCentral
16.
31.
go back to reference Hibbard J, Greene J (2013) What the evidence shows about patient activation: better health outcomes and care experiences; Fewer data on costs. Health Aff 32:207–214CrossRef Hibbard J, Greene J (2013) What the evidence shows about patient activation: better health outcomes and care experiences; Fewer data on costs. Health Aff 32:207–214CrossRef
51.
go back to reference Spielberger C, Gorusch R, Lushene R (1970) Manual for the State-Trait anxiety. Consulting Psychologists Press, California Spielberger C, Gorusch R, Lushene R (1970) Manual for the State-Trait anxiety. Consulting Psychologists Press, California
52.
go back to reference Spielberger C, Gorusch R, Lushene R (1983) Manual for the State-Trait anxiety inventory—form Y. Consulting Psychologists Press, Palo Alto, CA Spielberger C, Gorusch R, Lushene R (1983) Manual for the State-Trait anxiety inventory—form Y. Consulting Psychologists Press, Palo Alto, CA
Metadata
Title
The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1
Authors
Ashley Crook
Rebekah Kwa
Sarah Ephraums
Mathilda Wilding
Lavvina Thiyagarajan
Jane Fleming
Katrina Moore
Yemima Berman
Publication date
01-04-2022
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2022
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-021-00259-9

Other articles of this Issue 2/2022

Familial Cancer 2/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine